Comparison of overall and event-free survival of patients who recieved CLAG-M/sorafenib vs medically matched patients who received CLAG-M alone. Estimates of (A-D) OS and (E-H) EFS for 41 patients who received CLAG-M/sorafenib at the RP2D and 76 medically matched patients who received CLAG-M alone are shown (A,E) for all patients stratified based on (B,F) favorable, (C,G) intermediate, and (D,H) adverse cytogenetic/molecular disease risk. CLAG-M/S, CLAG-M/sorafenib.